Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Review Article

The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to consider

Abstract

The field of replication-selective oncolytic viruses (virotherapy) has exploded over the last 10 years. As with many novel therapeutic approaches, initial overexuberance has been tempered by clinical trial results with first-generation agents. Although a number of significant hurdles to this approach have now been identified, novel solutions have been proposed and improvements are being made at a furious rate. This article seeks to initiate a discussion of these hurdles, approaches to overcome them, and unique safety and regulatory issues to consider.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Southam CM . Present status of oncolytic virus studies Ann NY Acad Sci 1960 656–673

  2. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM . Experimental therapy of human glioma by means of a genetically engineered virus mutant Science 1991 252: 854–856

    Article  CAS  PubMed  Google Scholar 

  3. Lorence RM, Rood PA, Kelley KW . Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity J Natl Cancer Inst 1988 80: 1305–1312

    Article  CAS  PubMed  Google Scholar 

  4. Coffey M, Strong J, Forsyth P, Lee P . Reovirus therapy of tumors with activated ras pathway Science 1998 282: 1332–1334

    Article  CAS  PubMed  Google Scholar 

  5. Stojdl DF et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus Nat Med 2000 6: 821–825

    Article  CAS  PubMed  Google Scholar 

  6. Rommelaere J, Cornelis JJ . Antineoplastic activity of parvoviruses J Virol Methods 1991 33: 233–251

    Article  CAS  PubMed  Google Scholar 

  7. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM . Experimental therapy of human glioma by means of a genetically engineered virus mutant Science 1991 252: 854–856

    Article  CAS  PubMed  Google Scholar 

  8. Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [see comments] Science 1996 274: 373–376

    Article  CAS  PubMed  Google Scholar 

  9. Heise C et al. ONYX-015, an E1B gene–attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents [see comments] Nat Med 1997 3: 639–645

    Article  CAS  PubMed  Google Scholar 

  10. Mastrangelo M, Eisenlohr L, Gomella L, Lattime E . Poxvirus vectors: orphaned and underappreciated J Clin Invest 2000 105: 1031–1034

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Heise C et al. An adenovirus E1A mutant that demonstrates potent and selective antitumoral efficacy Nat Med 2000 6: 1134–1139

    Article  CAS  PubMed  Google Scholar 

  12. Fueyo J et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo Oncogene 2000 19: 2–12

    Article  CAS  PubMed  Google Scholar 

  13. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E . Intergeneric poliovirus recombinants for the treatment of malignant glioma [see comments] Proc Natl Acad Sci USA 2000 97: 6803–6808

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Miyatake S, Iyer A, Martuza RL, Rabkin SD . Transcriptional targeting of herpes simplex virus for cell-specific replication J Virol 1997 71: 5124–5132

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Wickham TJ, Shears TEL, Roelvink P et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins J Virol 1997 71: 8221–8229

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Alemany R, Curiel DT . The development of replicative adenoviruses for cancer therapy Clin Cancer Res 2000 6: 3395–3399

    Google Scholar 

  17. Heise C, Williams A, Olesch J, Kirn D . Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects Cancer Gene Ther 1999 6: 499–504

    Article  CAS  PubMed  Google Scholar 

  18. Ganly I et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 2000 6: 798–806

    CAS  PubMed  Google Scholar 

  19. Wu JT, Byrne HM, Kirn DH, Wein LM . Modeling and analysis of a virus that replicates selectively in tumor cells Bull Math Biol 2001 63: 731–768

    Article  CAS  PubMed  Google Scholar 

  20. Chinnadurai G . Adenovirus 2 Ip+ locus codes for a 19 kD tumor antigen that plays an essential role in cell transformation Cell 1983 33: 759–766

    Article  CAS  PubMed  Google Scholar 

  21. Sauthoff H, Heitner S, Rom W, Hay J . Deletion of the adenoviral E1B–19 kD gene enhances tumor cell killing of a replicating adenoviral vector Hum Gene Ther 2000 11: 379–388

    Article  CAS  PubMed  Google Scholar 

  22. Doronin K et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein J Virol 2000 74: 6147–6155

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Shenk T . In: Fields K, Howley P, eds Fields Virology Philadelphia: Lippincott-Raven 1996 2135–2137

    Google Scholar 

  24. Smith GL, Vanderplasschen A . Extracellular enveloped vaccinia virus. Entry, egress, and evasion Adv Exp Med Biol 1998 440: 395–414

    Article  CAS  PubMed  Google Scholar 

  25. Douglas J, Kim M, Sumerel L, Carey D, Curiel D . Efficient oncolysis by a replicating adenovirus in vivo is critically dependent on tumor expression of primary Ad receptors Cancer Res 2001 61: 813–817

    CAS  PubMed  Google Scholar 

  26. Rauen KA et al. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy Cancer Res 2002 62: 3812–3818

    CAS  PubMed  Google Scholar 

  27. Vasey P, Shulman L, Gore M, Kirn D, Kaye S . Phase I trial of intraperitoneal Onyx-015 adenovirus in patients with recurrent ovarian carcinoma Proc Am Soc Clin Oncol 2000 19: 1512 (Abstract)

    Google Scholar 

  28. Nemunaitis J et al. Selective replication and oncolysis in p53 mutant tumors with Onyx-015, an E1B–55 kD gene–deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial Cancer Res 2000 60: 6359–6366

    CAS  PubMed  Google Scholar 

  29. Mulvihill S, Warren R, Kirn D . Safety and feasibility of injection with an E1B–55 kD gene–deleted replication-selective adenovirus Onyx-015 into primary carcinomas of the pancreas: a phase I trial Gene Ther 2001 8: 308–315

    Article  CAS  PubMed  Google Scholar 

  30. Roelvink P, Mi G, Einfeld D, Kovesdi I, Wickham T . Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae Science 1999 286: 1568–1571

    Article  CAS  PubMed  Google Scholar 

  31. Suzuki K et al. A replicative adenovirus with enhanced infectivity shows improved oncolytic potency Clin Cancer Res 2001 7: 120–126

    CAS  PubMed  Google Scholar 

  32. Kirn D . Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 2001 8: 89–98

    Article  CAS  PubMed  Google Scholar 

  33. Toda T et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus Hum Gene Ther 1999 10: 2741–2755

    Article  Google Scholar 

  34. Herrlinger U et al. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector Gene Ther 1998 5: 809–819

    Article  CAS  PubMed  Google Scholar 

  35. Merritt J et al. Clinical phase I experience with INGN 201 (Ad-p53) in non-small cell lung cancer and head and neck cancer Cancer Gene Ther 1997 4: S12 (Abstract)

    Google Scholar 

  36. Reid T et al. Hepatic artery infusion of Onyx-015, a replication-selective adenovirus, in combination with 5-FU/leucovorin for gastrointestinal carcinoma metastatic to the liver: a phase I/II clinical trial Proc Am Soc Clin Oncol 2000 19: 953 (Abstract)

    Google Scholar 

  37. Reid T et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial Gene Ther 2001 8: 1618–1626

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Nemunaitis J et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity Gene Ther 2001 8: 746–759

    Article  CAS  PubMed  Google Scholar 

  39. Pecora AL et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers J Clin Oncol 2002 20: 2251–2266

    Article  CAS  PubMed  Google Scholar 

  40. Kirn D . Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer Oncogene 2000 1: 6660–6668

    Article  Google Scholar 

  41. Vanderplasschen A, Mathew E, Hollinshead M, Sim RB, Smith GL . Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope Proc Natl Acad Sci USA 1998 95: 7544–7549

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Heise C, Williams A, Xue S, Propst M, Kirn D . Intravenous administration of ONYX-015, a selectively-replicating adenovirus, induces antitumoral efficacy Cancer Res 1999 59: 2623–2628

    CAS  PubMed  Google Scholar 

  43. Ikeda K, Chiocca N . Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited anti-viral responses Nat Med 1999 5: 881–887

    Article  CAS  PubMed  Google Scholar 

  44. Gnant MF, Puhlmann M, Alexander HR Jr, Bartlett DL . Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice Cancer Res 1999 59: 3396–3403

    CAS  PubMed  Google Scholar 

  45. Gnant MF et al. Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases J Natl Cancer Inst 1999 91: 1744–1750

    Article  CAS  PubMed  Google Scholar 

  46. Kirn D, Warren R . Liver-directed therapy with p53-targeted adenoviruses: clinical trial results Surg Clin North Am 2002 (In press)

  47. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL . Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas Nat Med 1995 1: 938–943

    Article  CAS  PubMed  Google Scholar 

  48. Markert J et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial Gene Ther 2000 7: 867–874

    Article  CAS  PubMed  Google Scholar 

  49. Hermiston T . Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer J Clin Invest 2000 105: 1169–1172

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Toda M, Martuza RL, Kojima H, Rabkin SD . In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity J Immunol 1998 160: 4457–4464

    CAS  PubMed  Google Scholar 

  51. Wildner O, Blaese RM, Morris JM . Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase Cancer Res 1999 59: 410–413

    CAS  PubMed  Google Scholar 

  52. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH . A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy [see comments] Hum Gene Ther 1998 9: 1323–1333

    Article  CAS  PubMed  Google Scholar 

  53. Kurihara T, Brough DE, Kovesdi I, Kufe DW . Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen J Clin Invest 2000 106: 763–771

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Russell SJ . Gene therapy for cancer Lancet 1992 339: 1109–1110

    Article  CAS  PubMed  Google Scholar 

  55. Haag A et al. Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice Hum Gene Ther 2000 11: 597–609

    Article  CAS  PubMed  Google Scholar 

  56. McCart JA et al. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression Gene Ther 2000 7: 1217–1223

    Article  CAS  PubMed  Google Scholar 

  57. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proc Natl Acad Sci USA 1993 90: 3539–3543

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David Kirn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vile, R., Ando, D. & Kirn, D. The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to consider. Cancer Gene Ther 9, 1062–1067 (2002). https://doi.org/10.1038/sj.cgt.7700548

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700548

Keywords

This article is cited by

Search

Quick links